Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  uniQure  /  Wat is de waarde van uniQure?

Ontvang nu dagelijks onze kooptips!

word abonnee

uniQure« Terug naar discussie overzicht

Wat is de waarde van uniQure?

7.806 Posts
Pagina: «« 1 ... 284 285 286 287 288 ... 391 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 20 juni 2017 08:45
    quote:

    Beurs2020 schreef op 20 juni 2017 08:40:

    DZR, je reactie toont dat je niet tegen kritiek kunt. Erger is dat je dat vervolgens denkt te pareren met bijdragen, die weinig inhoudelijke kennis vermoeden. Maar wat kan jou dat schelen, je hebt weer lekker ongenuanceerd gestookt.
    Als ik jou was dan zou ik QURE omwisselen in Galapagos, dan heb je tenminste een kans.
    Ik heb trouwens jaren geleden al Genmab en Galapagos getipt op dit forum.
  10. ch@rter 22 juni 2017 22:50
    Verkooporder geplaatst op 6,40 voordat ik naar Genua vertrok .. niet gehaald zie ik net. (Was ook wel iets too much)

    @ivet
    Zowel met of zonder nieuws is er geen pijl op te trekken.

    Als de shorters m laten vieren tot 6,5 a 6,6 nemen zij ongetwijfeld nwe posities in.

    Hopen maar een keer op een doorbraak, shorts out koers UP .. i know hopen liggen buiten en plakken zo nu en dan onder je schoen.

    Morgen nwe poging, moet lukken 6,40
  11. ch@rter 23 juni 2017 11:13
    P.A.W. Capital Corp Invests $867,000 in uniQure N.V. (QURE)
    Posted by Wayne Landers on Jun 22nd, 2017 // No Comments
    uniQure N.V. logoP.A.W. Capital Corp bought a new stake in uniQure N.V. (NASDAQ:QURE) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 150,000 shares of the biotechnology company’s stock, valued at approximately $867,000. P.A.W. Capital Corp owned 0.59% of uniQure N.V. at the end of the most recent quarter.
    Several other large investors have also recently modified their holdings of the company. FMR LLC boosted its stake in shares of uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock valued at $8,661,000 after buying an additional 323,345 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of uniQure N.V. by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock valued at $253,000 after buying an additional 14,702 shares in the last quarter. Oxford Asset Management purchased a new stake in shares of uniQure N.V. during the first quarter valued at $100,000. Perceptive Advisors LLC purchased a new stake in shares of uniQure N.V. during the fourth quarter valued at $7,089,000. Finally, City Financial Investment Co Ltd purchased a new stake in shares of uniQure N.V. during the fourth quarter valued at $1,492,000. Institutional investors and hedge funds own 30.50% of the company’s stock
  12. ch@rter 23 juni 2017 11:17
    uniQure N.V. (NASDAQ:QURE) last session’s volume of 0.22 million shares was higher than its average volume of 0.11 million shares. The stock, after opening at $5.35, hit $5.88 through the close by scoring 10.53%.

    uniQure N.V. (QURE) Analyst Opinion
    uniQure N.V. has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 3.35% of shares outstanding. The stock spiked 0.17% last month and is up 5 this year. Wall Street is only getting more bullish on the stock, with 6 of analysts who cover QURE having a buy-equivalent rating. Analysts have placed a $12.77 price target on uniQure N.V., suggesting a 117.18% gain from recent close. It’s currently trading about -39.52% below its 52-week high
  13. Fartknock 23 juni 2017 14:32
    tools.eurolandir.com/tools/Pressrelea...

    uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis (ISTH) Congress

    ~ Updated, Long-term Results from the Phase I/II Dose-Escalating Study of AMT-060 to be Presented on Monday, July 10, 2017 ~

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two abstracts have been accepted for presentation at the International Society on Thrombosis and Hemostasis (ISTH) Congress held in Berlin, Germany, July 8 - 13, 2017.

    "The data to be featured in an oral presentation at ISTH now demonstrate long-term safety, efficacy and the potential for broad application of AAV5 in hemophilia B," stated Matthew Kapusta, chief executive officer of uniQure. "We also look forward to the presentation of clinical data demonstrating successful and effective transduction in patients with pre-existing neutralizing antibodies to AAV5, further supporting our belief that our AAV5-based gene therapies may provide clinical benefits to nearly all patients suffering from hemophilia B and other severe diseases."

    Specific details on uniQure's presentations at ISTH include:

    •Title: Updated Results from a Dose-escalating Study in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy: Up to 1.5 Years Follow-up
    Oral Session Title: Gene Therapy for Hemophilia: Clinical
    Date and Time: Monday, July 10, 2017, 6:00 p.m. CET / 12:00 p.m. EDT
    Location: Hall B, CityCube Berlin, Messedamm 26, 14055, Berlin

    Updated data on AMT-060 will be presented by study investigator Professor Frank W. Miesbach, M.D. Ph.D. of the Universitäts Klinikum Frankfurt, Germany. AMT-060 is an AAV5-FIX gene therapy developed by uniQure using its proprietary insect-cell based technology platform. The updated data will include up to 1.5 years of follow-up on the first patient cohort receiving 5x1012 gc/kg and up to a year of follow-up on the second patient cohort receiving a higher dose of 2x1013 gc/kg.

    •Title: Pre-existing anti-AAV5 neutralizing antibodies measured using a highly sensitive assay in sera of Hemophilia B patients in a Phase I/II clinical trial of AMT-060 do not predict efficacy of AAV5-mediated liver-directed gene transfer
    Poster Session Date and Time: Tuesday, July 11, 2017, 12:00 pm CET / 6:00 a.m. EDT
    Location: Exhibition Hall 4.2, CityCube, Messedamm 26, 14055, Berlin
7.806 Posts
Pagina: «« 1 ... 284 285 286 287 288 ... 391 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 910,59 +0,71%
EUR/USD 1,0774 +0,03%
FTSE 100 8.433,76 +0,63%
Germany40^ 18.773,50 +0,00%
Gold spot 2.361,30 +0,02%
NY-Nasdaq Composite 16.340,87 -0,03%

Stijgers

Accsys
+5,43%
CM.COM
+2,92%
NX FIL...
+2,63%
RANDST...
+2,61%
ForFar...
+2,43%

Dalers

Kendrion
-2,99%
UMG
-2,95%
Alfen ...
-2,63%
EBUSCO...
-2,29%
VIVORY...
-1,85%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!